The Osteogenesis Imperfecta drugs in development market research report provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Osteogenesis Imperfecta. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Osteogenesis Imperfecta by 16 companies/universities/institutes. The top development phase for Osteogenesis Imperfecta is preclinical with eight drugs in that stage. The Osteogenesis Imperfecta pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Osteogenesis Imperfecta pipeline products market are: Sanofi, BioSenic and Ultragenyx Pharmaceutical.

The key targets in the Osteogenesis Imperfecta pipeline products market include Sclerostin (SOST), Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4), and microRNA 29B (MIR29B).

The key mechanisms of action in the Osteogenesis Imperfecta pipeline product include Sclerostin (SOST) Inhibitor with four drugs in Phase III. The Osteogenesis Imperfecta pipeline products include four routes of administration with the top ROA being Intravenous and seven key molecule types in the Osteogenesis Imperfecta pipeline products market including Monoclonal Antibody, and Small Molecule.

Osteogenesis Imperfecta overview

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects, and respiratory problems. Treatment includes bisphosphonates and surgery.

For a complete picture of Osteogenesis Imperfecta’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.